TY - JOUR
T1 - Seroconversion rates among different designs of COVID-19 vaccines
T2 - a network meta-analysis of randomized controlled trials
AU - Soegiarto, Gatot
AU - Fajar, Jonny Karunia
AU - Wulandari, Laksmi
AU - Anshory, Muhammad
AU - Ilmawan, Muhammad
AU - Asmiragani, Anisa
AU - Illiyana, Himma
AU - Adam, Azaria
AU - Lamadi, Sutini
AU - Sa'adah, Umi
AU - Yuantoko, Tubagus
AU - Nanda, Esi
AU - Rachmawati, Farida
AU - Rahmadani, Nabila
AU - Talilah, Randy
AU - Katipana, Madyline
AU - Susanto, Sharon
AU - Hindom, Maria
AU - Anjasari, Ufi
AU - Hidayah, Nur
AU - Fadilla, Nanda
AU - Lekatompessy, Vanela
AU - Phoenna, Uzi
AU - Tamara, Fredo
AU - Kartini, Dessy Aprilia
AU - Mahendra, Aditya Indra
AU - Permana, Andi
AU - Pasaribu, Erwin Alexander
AU - Dhama, Kuldeep
AU - Harapan, Harapan
N1 - Funding Information:
The author(s) declared that no grants were involved in supporting this work.
Publisher Copyright:
Copyright: © 2022 Soegiarto G et al.
PY - 2022
Y1 - 2022
N2 - BACKGROUND: The COVID-19 vaccination program, which uses various types of vaccines, has been applied since the beginning of 2021. However, the efficacy in the context of seroconversion rate remains unclear. OBJECTIVE: To assess the seroconversion rates among different COVID-19 vaccines using a network meta-analysis approach. METHODS: A network meta-analysis of randomized controlled trials (RCTs) was conducted during the study period. Data of interest, such as seroconversion rate and the type of COVID-19 vaccine, were extracted from each study. The analysis was performed using single-arm analysis by calculating the cumulative seroconversion rate. A network meta-analysis was conducted using the Bayesian method. RESULTS: A total of 31 RCTs were included in our analysis. Our pooled calculation revealed that the seroconversion rates of inactivated messenger ribonucleic acid (mRNA), protein subunit, and vector COVID-19 vaccines during the follow-up periods were 93.2%, 93.9%, 65.3%, and 54.7%, respectively, at ≤ 15 days; 96.0%, 94.8%, 91.2%, and 89.7%, respectively, between days 16–30; and 98.5%, 98.6%, 98.5%, and 96.2%, respectively, between days 31–60.The indirect comparison revealed that in the follow-up periods of ≤ 15 and 16–30 days, the inactivated and mRNA COVID-19 vaccines had superior seroconversion rates compared with those of the protein subunit and vector vaccines. In the follow-up period of 31–60 days, the highest seroconversion rates were found in the inactivated, mRNA, and protein subunit COVID-19 vaccines. CONCLUSION: This study provides valuable information regarding the comparison of seroconversion rates of COVID-19 vaccines.
AB - BACKGROUND: The COVID-19 vaccination program, which uses various types of vaccines, has been applied since the beginning of 2021. However, the efficacy in the context of seroconversion rate remains unclear. OBJECTIVE: To assess the seroconversion rates among different COVID-19 vaccines using a network meta-analysis approach. METHODS: A network meta-analysis of randomized controlled trials (RCTs) was conducted during the study period. Data of interest, such as seroconversion rate and the type of COVID-19 vaccine, were extracted from each study. The analysis was performed using single-arm analysis by calculating the cumulative seroconversion rate. A network meta-analysis was conducted using the Bayesian method. RESULTS: A total of 31 RCTs were included in our analysis. Our pooled calculation revealed that the seroconversion rates of inactivated messenger ribonucleic acid (mRNA), protein subunit, and vector COVID-19 vaccines during the follow-up periods were 93.2%, 93.9%, 65.3%, and 54.7%, respectively, at ≤ 15 days; 96.0%, 94.8%, 91.2%, and 89.7%, respectively, between days 16–30; and 98.5%, 98.6%, 98.5%, and 96.2%, respectively, between days 31–60.The indirect comparison revealed that in the follow-up periods of ≤ 15 and 16–30 days, the inactivated and mRNA COVID-19 vaccines had superior seroconversion rates compared with those of the protein subunit and vector vaccines. In the follow-up period of 31–60 days, the highest seroconversion rates were found in the inactivated, mRNA, and protein subunit COVID-19 vaccines. CONCLUSION: This study provides valuable information regarding the comparison of seroconversion rates of COVID-19 vaccines.
KW - COVID-19; vaccine; seroconversion; efficacy; immunization
UR - http://www.scopus.com/inward/record.url?scp=85152944853&partnerID=8YFLogxK
U2 - 10.12688/f1000research.110281.1
DO - 10.12688/f1000research.110281.1
M3 - Review article
AN - SCOPUS:85152944853
SN - 2046-1402
VL - 11
JO - F1000Research
JF - F1000Research
M1 - 299
ER -